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ABSTRACT. The stock market's valuation of selected public firms within the biotechnology industry has been
analyzed to measure the performance of specific companies within a subset of the industry and the per-
formance of this subset of the biotechnology industry within a larger universe of publicly traded companies.
The objective of the study was to analyze the performance of the individual firm into components attributable
to 1) the overall performance of the econony; 2) the industry performance compared with other industries; and
3) the specific performance of the individual companies compared with other firms within the industry. The
method of analysis is independent of conventional profit-and-loss approaches. The stock market alone is used
for the evaluations. The changes in market value are the sum of the three components adjusted for the size
of the firm.
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INTRODUCTION
The usual method used to evaluate the financial per-
formance of individual firms is to analyze operating state-
ments and balance sheets. This conventional method of
evaluation is not adequate for the case of early-entry firms
in an industry based on new technologies (Office of Tech-
nology Assessment 1984a, 1984b). This is recognized in
business periodicals by vague references to technology-
driven industries as distinguished from profit-driven
industries.
The purpose of this paper is to probe the changing
market valuations of early-entry firms in biotechnology
to develop a measurement system that will quantify indi-
vidual performance, even if the companies are in a re-
search mode with associated losses of substantial mag-
nitude (U.S. Dept. of Commerce, International Trade
Administration 1984). Most analysts assume that strong
statements can be used to predict future positive changes
in stock valuation. There is, of course, a correlation
between strong financial data and future valuation by
the market, but for companies losing money the logic
that connects the variables is arcane.
METHOD OF EVALUATION
The method for evaluation proposed in this paper is straight-
forward, and the logic is likewise direct. The market itself is used to
evaluate the performance of individual firms. The change in a focal
company valuation (denoted as size) by the market is decomposed into
six terms: 1) a term for all-industry performance by a hypothetical
firm of average size; 2) an adjustment to the all-industry first term to
compensate for the actual size of the focal firm; 3) an industry-specific
term for a hypothetical firm of average size in the industry; 4) an
adjustment to the industry-specific term to allow for the difference in
size of the focal firm from the average; 5) a firm-specific term for a
hypothetical firm of average size; and 6) an adjustment to the firm-
specific term to allow for the difference in size of the focal firm from
the hypothetical average size firm. The difference in market valuation
from one date to another is exactly accounted for by the six terms. The
aggregate common stock valuation on a corresponding date is ob-
tained by multiplying the number of outstanding shares by the clos-
ing value of shares traded (Data obtained from Standard and Poor's
Daily Stock Price Record Over-The-Counter; Standard and Poor Cor-
poration 1983, 1985).
MATHEMATICAL RELATIONSHIPS
A relative rate of change, X, is defined as follows:
* XP — XB
The starred symbol denotes the relative rate of change;
the subscript F denotes the value of all outstanding com-
mon stock at the final time; and the subscript B denotes
the value of all outstanding common stock at the base
time. This expression is used with the understanding that
the difference between the base time and the final time
is fixed. In this study the time interval was two years.
Let X denote the value of a particular stock. The index
of change is denoted as Z, and is the ratio of the value at
the final time to the value at the base time. The index of
change for that stock is therefore expressed as follows:
The values for NF and NB are simply the Standard-and-
Poor Composite Index values on the final date and the
base date. Using the index concept eliminates the need
for evaluating all stocks individually and summing for
the base date and the final date.
The market valuation, e, for a focal firm (size) is the
sum of the market valuation for a hypothetical firm of
average size in the industry (h) and the market valuation
for the residual size (r), or
e — h + r.
If the focal company valuation is greater than the aver-
age valuation, r is positive; if the company valuation is
smaller than average, the residual, r, is negative. (Note
that Ae = ee. Also note that:
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Consider the diagram (Fig. 1) that indicates the re-
lationship among rates of change. N denotes the rate of
change of the composite stock group; n denotes the rate
of change of the focal industry; and e denotes the rate of
change of the focal company. Thus,
and
The equation above is an identity. Each term consists
of a size factor and a rate-of-change factor (Janson and
Pavlakovic 1983, Janson et al. 1984). In the equation,
the change in valuation, ee , is expressed as the sum of six
terms. The terms with the factor h correspond to results
for the focal firm, providing that the focal firm is of
average size. If the firm is of average size, the residual
value, r, is equal to zero. Also, h and ZN and n and N
are values that are the same for all companies in the
industry. Only e is company-specific. Therefore, the fifth
term is the term that measures company performance in
comparison with other companies in the industry on an
equal basis (i.e., for an equalized size h). The value of the
fifth term is an index of company performance within
the industry.
The six terms can be arranged in a matrix as indicated
in Figure 2. For an average size firm in the industry, all
values in column r are equal to zero. For an average
performing company within the industry, (e — n) is
equal to zero. In this case terms 5 and 6 are equal to zero.
For a company of average size in the specified industry,
operating with average industry performance, the con-
tribution to growth is the sum of term 1 and term 3
(Fig. 2). Term 1 is the all-economy effect on an average
size company. Term 5 is uniquely the accomplishment of
the focal firm in a relative sense, because Term 5 pre-
sumes that the focal company is of average industry mar-
ket value. Term 3 is an industry effect on an average size
company. Terms 2 , 4 , and 6 correct for the specific size
(market value) of the company.
If the company is smaller than average, r is negative.
If the company performance is less than the industry
average, (e — n) is also negative but the product is
positive. Where growth rates are negative, a negative
FIGURE 1. Market evaluation growth rates. /ST, n, and e denote the
relative rates of change in the market evaluation for the composite
stock group, industry group, and focal company, respectively. The
variables are shown as slopes and differences in slopes.
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FIGURE 2. Market evaluation matrix relating growth factors and
size factors. Size refers to market value (shares outstanding X market
price); h refers to average size of a company within the ith industry;
r refers to the difference in size from average for a focal company;
starred symbols denote relative rates of change. Z denotes index of
composite stock group; N denotes size of composite stock group; n
denotes size of zth-industry stock group; e denotes size of focal com-
pany.
value for r mitigates the problem, because the algebraic
product will be positive. This simply means that where
growth rates are negative, the decline in market valuation
would be exacerbated if the focal firm were larger than
average (e > h\ r > 0). If the firm is smaller than aver-
age (e < h; r < 0), the decline in market value will be
less than for a firm of average size in market value. On
the other hand, if the growth rate is positive, larger
companies have better results than smaller ones. Only
Term 5 allows a comparison among firms of the industry
on an equal basis, and measures the specific company
performance in the industry based on a hypothetical size
equal to the industry average size.
RESULTS AND DISCUSSION
Biotechnology companies present a serious problem of
valuation. Of course, the market automatically adjusts
the supply and demand for the stock, but the problem is
one of evaluating the worth of a company that is typically
suffering from substantial losses. The results, after a
time, are incredible. For example, Biotechnica Inter-
national had an equity per share of $0.35 in April, 1986,
with a bid price of $8.50 and an asking price of $9-00.
At that time almost 4 million shares were outstanding,
and about 50,000 shares traded monthly (Biotechnology
News 1986). Substantial losses are continuing. This is
not untypical. Investors are willing to pay great pre-
miums in order to buy into biotechnology.
The change in valuation of a stock over time can be
analyzed (decomposed) into three elements that corre-
spond to the source of the impetus for change. First, part
of the change in stock valuation is attributable to the
larger securities market. In a "bull market" with heavy
trading, all equities are influenced by the psychology of
the general market. The physical assets and the propor-
tion that is equity may not have changed at all, and yet
the average market values of all equities are higher than
before. Second, the industry component of the change in
valuation reflects structural changes in the economy. In
the long run, as the economy matures, per capita real
income increases, and the percentage of income spent on
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a commodity will change. For this reason, the structures
of demand and production change. These are industry-
wide influences on the valuation of a particular company's
stock. For example, as an economy increases in wealth,
the demand for products in saturated markets does not
increase proportionately (Engle's Law). At the same time,
the demand for innovative, high value-added products
may increase more than proportionately. Finally, the
variable company component of the change in stock valu-
ations corresponds to the third source of the impetus for
change. This component is firm-specific, and is assign-
able to individual company performance. Company-
specific changes correspond to adaptations by the firm to
the changing environment with results that may be bet-
ter or worse than the adaptation by other firms in the
same industry. For example, in the late 1970s, Chrysler
responded more quickly than General Motors and Ford to
the flood of imported Japanese cars by rapidly altering
product lines to produce smaller models.
The three categories of influence are like forces; the
valuation of the company corresponds to mass. When the
company is larger than average, the effects are amplified.
If the overall stock market reverses (measured by the
Standard-and-Poor Composite Index), all constituent in-
dustry averages will decline. On the other hand, relative
change among industry averages is primarily reflective of
structural changes in patterns of commodity demand on
one side of the economic problem and structural changes
in technology and input proportions on the supply side
of commodity production.
The findings have been tabulated (Table 1) for the
10 firms defined as a subset of the industry. Genentech
was deliberately excluded from the study because its
current transition from a research firm without major
products to a pharmaceutical firm implies a different
classification (see Olson 1986, Wagner 1984). Terms 1
and 2 (Fig. 2) have been added together (column 1 in
Table 1) to present the general market expectation for the
specified firm in the 1983-1985 stock market context.
The data in Table 1 indicate that Cetus, Biogen, and
Damon Biotech should be clear leaders, because they are
the largest companies in a rising all-industry stock mar-
ket.
The cell values in Term 5 are divorced from national,
regional, and size effects (Table 1). Term 5 measures
specific performance of the firm in a fair comparison,
adjusted for a hypothetical average size. Cetus is the clear
winner, with Immunex and Amgen also being strong
performers. The dismal comparative performances of
Genetic Engineering, Immuno Genetic, Gama, Molecu-
lar Genetic, and Damon Biotech were masked to a great
extent by the general market movement and the industry
performance.
Cetus was the overwhelming winner in increased mar-
ket valuation during the two year period of 1984-1985,
and investors were justified in their confidence. The large
size of Cetus amplified its excellent performance. Biogen,
Amgen, and, to a lesser extent, Immunex also had very
substantial increases in market value. The increases in
valuation of Immunex and Amgen were buttressed by
excellent firm-specific performance. Both firms had a
capitalization too small (less than average) to amplify
their excellent performance. Immunex appears to be un-
dervalued. This was the only company whose change in
market value was less than its firm-specific contribution
to the change.
CONCLUSION
The method illustrated in this study allows compara-
tive valuation of individual companies for an industry
still in a research phase. Because the biotechnology in-
dustry is still in the formative stage of development,
profits are usually non-existent, financial requirements
are substantial, and disappointment is mixed with opti-
mism. The ultimate products derived from research in
biotechnology will be far-reaching and of great benefit to
mankind. In the long term, methods of production using
diverse biotechnologies will be used for chemical con-
version, for plant and animal food production, and for
health products. The capital requirements needed for this
fledgling industry require analysis of individual company
performance and potential. The method presented pro-
vides procedures to comparatively evaluate the perfor-
mance of early-entry firms in an industry based on new
technologies.
TABLE 1
Composition of change in market value ^(millions of dollars) for 10 biotechnology firms, 1983-1985.
The equation for determining changes in market value is:
h(ZN - 1) + r(ZN -
Firms
Amgen
Biogen
Cetus
Damon Biotech
Gama
Genetic Eng.
Monoclonal Anti.
Immunex
Immuno Genetic
Molecular Gen.
Column Total
Terms 1 + 2
21.13
55.12
67.24
42.93
12.64
3.34
7.90
10.46
7.49
20.25
248.5
Term 3
29.29
29.29
29.29
29.29
29.29
29.29
29.29
29.29
29.29
29.29
292.9
Term 4
-4.39
35.68
49.96
21.33
-14.39
-25.35
-19-98
-16.97
-20.46
-5.43
0
Term 5
28.40
-22.19
86.09
-52.36
-86.09
-125.14
6.21
52.36
-93.19
-63.01
-268.90
Term 6
-4.26
-27.03
146.86
-38.09
42.29
108.30
-4.24
-30.33
65.09
11.67
270.26
ee
70.17
70.87
379-44
3.10
-16.26
-9.56
19.18
44.81
-11.78
-7 .23
542.74
1983
Value
75.45
196.87
240.15
153.31
45.15
11.94
28.21
37.34
26.76
72.31
887.49
*Standard and Poor's Corporation (1983, 1985). Daily Stock Price Record Over-the-Counter (Oct., Nov., Dec.)
Average
h = 88.75
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